4. Progression‐free survival (PFS) for platinum combination versus non‐platinum therapy.
Author, year | n (elderly) | Median PFS (95% CI) | HR (95% CI) | P value | |
Non‐platinum single agent | Platinum‐based combination | ||||
Quoix 2011b | 451 | 2.8 (2.6‐3.7) months | 6.0 (5.5‐6.8) months | 0.51 (0.42‐0.62) | < 0.0001 |
Abe 2011 | 233 | 4.4 (3.4‐5.1) months | 4.7 (4.1‐5.8) months | 0.92 (0.71‐1.20) | 0.55 |
Chen 2008 | 65 | 3.1 (NR) months | 5.2 (NR) months | 0.66 (0.42‐1.04) | 0.07 |
Georgoulias 2004 | 70 | 2.5 (NR) months | 4.3 months | 0.86 (0.58‐1.29) | 0.48 |
Boni 2012 | 101 | NR | NR | 0.61 (0.40‐0.93) | 0.02 |
Kubota 2008 | 118 | 5.8 (MR) months | 5.8 (NR) months | 0.90 (0.62‐1.31) | 0.58 |
Georgoulias 2005 | 82 | 4.5 (NR) months | 4.6 (NR) months | 1.10 (0.70‐1.73) | 0.68 |
Laack 2004 | 43 | 10.9 (3.4‐24.9) weeks | 17.1 (8.4‐32.4) weeks | 0.71 (0.35‐1.44) | 0.34 |
Georgoulias 2001 | 71 | 2.5 (NR) months | 5.1 (NR) | 0.81 (0.50‐1.31) | 0.39 |
95% CI: 95% confidence interval; HR: hazard ratio; NR: not reported; PFS: progression‐free survival.